Multi-Omics Analysis Reveals Distinct Metabolomic and Proteomic Signatures in Parkinson’s Disease with and without REM Sleep Behavior Disorder
Multi-Omics Analysis Reveals Distinct Metabolomic and Proteomic Signatures in Parkinson’s Disease with and without REM Sleep Behavior Disorder
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
Rapid eye movement sleep behavior disorder (RBD) is the most specific prodromal marker of Parkinson disease (PD), affecting 40-50% of PD patients. PD with RBD (RBD-PD) represents a clinically aggressive subtype marked by more severe motor and non-motor symptoms, prominent autonomic dysfunction, and accelerated disease progression, yet its underlying pathogenesis remains poorly understood. Given the recognized role of neuroinflammation in PD, plasma inflammatory proteins were profiled using the Olink Explore 384 Inflammation Panel in 226 samples from patients with RBD-PD (n=76), PD patients without RBD (non-RBD-PD, n =76), and healthy controls (Ctrl, n=74).